- Home
- FRA vs MREO Comparison
FRA vs MREO Comparison
Compare FRA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRA
- MREO
- Stock Information
- Founded
- FRA 2003
- MREO 2015
- Country
- FRA United States
- MREO United Kingdom
- Employees
- FRA N/A
- MREO N/A
- Industry
- FRA Investment Bankers/Brokers/Service
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- FRA Finance
- MREO Health Care
- Exchange
- FRA Nasdaq
- MREO Nasdaq
- Market Cap
- FRA 449.1M
- MREO 424.5M
- IPO Year
- FRA N/A
- MREO N/A
- Fundamental
- Price
- FRA $12.87
- MREO $2.85
- Analyst Decision
- FRA
- MREO Strong Buy
- Analyst Count
- FRA 0
- MREO 7
- Target Price
- FRA N/A
- MREO $7.71
- AVG Volume (30 Days)
- FRA 165.4K
- MREO 1.2M
- Earning Date
- FRA 01-01-0001
- MREO 08-12-2025
- Dividend Yield
- FRA 11.06%
- MREO N/A
- EPS Growth
- FRA N/A
- MREO N/A
- EPS
- FRA N/A
- MREO N/A
- Revenue
- FRA N/A
- MREO N/A
- Revenue This Year
- FRA N/A
- MREO N/A
- Revenue Next Year
- FRA N/A
- MREO $54.07
- P/E Ratio
- FRA N/A
- MREO N/A
- Revenue Growth
- FRA N/A
- MREO N/A
- 52 Week Low
- FRA $11.33
- MREO $1.58
- 52 Week High
- FRA $13.10
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- FRA 56.56
- MREO 64.74
- Support Level
- FRA $12.41
- MREO $2.61
- Resistance Level
- FRA $12.96
- MREO $2.85
- Average True Range (ATR)
- FRA 0.10
- MREO 0.17
- MACD
- FRA -0.01
- MREO 0.03
- Stochastic Oscillator
- FRA 60.00
- MREO 88.83
About FRA Blackrock Floating Rate Income Strategies Fund Inc
Blackrock Floating Rate Inc Stra Fd Inc is a United States-based diversified closed-ended management investment company. The Fund's investment objective is to provide shareholders with high current income and preservation of capital with investment in a diversified, leveraged portfolio consisting of floating-rate debt securities and instruments.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).